Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 3, 2015, Pages 540-545

  Wu, Shanshan ^a   Xia, Yinyin ^b   Lv, Xiaozhen ^a   Tang, Shaowen ^a   Yang, Zhirong ^a   Zhang, Yuan ^a   Wang, Xiaomeng ^d   Hu, Daiyu ^e   Liu, Feiying ^f   Yuan, Yanli ^b   Tu, Dehua ^c   Sun, Feng ^a   Zhou, Lin ^b   Zhan, Siyan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Beijing Research Institute for Tuberculosis Control   (China)

^d ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e Chongqing Municipal Center for Disease Control and Prevention   (China)

^f Center for Disease Control and Prevention in Guangxi Zhuang Autonomous Region   (China)

Author keywords

Cohort; Hepatoprotectors; Liver injury; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHINESE DRUG; ETHAMBUTOL; GLUCURONOLACTONE; HEPATITIS B SURFACE ANTIGEN; HU GAN PIAN; INOSINE; ISONIAZID; LIVER ENZYME; PYRAZINAMIDE; RIFAMPICIN; SILYMARIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; GLUCURONIC ACID; PROTECTIVE AGENT;

ADULT; ANTI TUBERCULOSIS DRUG INDUCED LIVER INJURY; ARTICLE; CHINESE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INCOME; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SPUTUM SMEAR; TOXIC HEPATITIS; TREATMENT DURATION; TUBERCULOSIS; DRUG-INDUCED LIVER INJURY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; GLUCURONIC ACID; HUMANS; INOSINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; SILYMARIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923228201     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12717     Document Type: Article

References (23)

1. World Health Organization. Global Tuberculosis Control: WHO Report 2012. Geneva: WHO, 2012. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1
2. World Health Organization. An Expanded DOTS Framework for Effective Tuberculosis Control. Stop TB Communicable Diseases. Geneva: WHO, 2002. Cited 13 Feb 2014. Available from URL: http://whqlibdoc.who.int/hq/2002/WHO_CDS_TB_2002.297.pdf?ua=1
3. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 2003; 167: 1472-1477.
4. Kaona FA, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health 2004; 4: 68.
5. Wares DF, Singh S, Acharya AK, Dangi R. Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. Int. J. Tuberc. Lung Dis. 2003; 7: 327-335.
6. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003; 362: 887-899.
7. Shang P, Xia Y, Liu F etal. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS ONE 2011; 6: e21836.
8. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int. J. Tuberc. Lung Dis. 2002; 6: 699-705.
9. Huang YS, Chern HD, Su WJ etal. Cytochrome P4502E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
10. Liu Q, Garner P, Wang Y, Huang B, Smith H. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health 2008; 8: 365.
11. Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig. Liver Dis. 2007; 39: 293-304.
12. Hu DY, Liu XY, Chen J etal. Direct observation and adherence to tuberculosis treatment in Chongqing, China: a descriptive study. Health policy Plan 2008; 23: 43-55.
13. Huang AJ, Xia YY, Zhan SY, Zhang YW, Shu Z. Effectiveness and safety of preventive usage of liver protective drugs during anti-tuberculosis therapy: a systematic review of clinical trials in China. Zhonghua Liu Xing Bing Xue Za Zhi 2010; 31: 826-827.
14. Xia YY, Hu DY, Liu FY etal. Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). BMC Public Health 2010; 10: 267.
15. Saukkonen JJ, Cohn DL, Jasmer RM etal. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 2006; 174: 935-952.
16. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 2008; 23: 192-202.
17. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am. J. Epidemiol. 2006; 163: 1149-1156.
18. World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicines. Geneva: WHO, 2000. Cited 13 Feb 2014. Available from URL: http://www.paho.org/Spanish/AD/THS/EV/PM-WHOTraditional-medicines-research-evaluation.pdf
19. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav. Res. 2011; 46: 399-424.
20. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006; 9: 377-385.
21. Suk KT, Kim DJ, Kim CH etal. A prospective nationwide study of drug-induced liver injury in Korea. Am. J. Gastroenterol. 2012; 107: 1380-1387.
22. Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes. Cell Biochem. Biophys. 2012; 64: 77-83.
23. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003; 123: 102-106.